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ABSTRACT 
Joseph Vincent Lomino: Triggered folding of a Mycobacterium tuberculosis adhesin, heparin 
binding hemagglutinin adhesin (HBHA). 
(Under the direction of Matthew R. Redinbo) 
The heparin-binding hemagglutinin (HBHA) is a surface adhesin on human pathogen 
Mycobacterium tuberculosis.  Previously, it has been shown that HBHA exists as a dimer in 
solution. We investigated the detailed nature of this dimer using circular dichroism spectroscopy 
and analytical ultracentrifugation techniques.  We demonstrate that the heparan sulfate (HS) 
binding region does not play a role in dimerization in solution, while the linker region between 
the predicted N-terminal coiled-coil and the C-terminal HS binding region does impact dimer 
stability.  The majority of contacts responsible for dimerization, folding, and stability lie within 
the predicted coiled-coil region of HBHA, while the N-terminal helix preceding the coiled-coil 
appears to trigger the folding and dimerization of HBHA.  Constructs lacking this initial helix or 
containing site-specific mutations produce non-helical monomers in solution. Thus, we show that 
HBHA dimerization and folding are linked, and that the N-terminal region of this cell surface 
adhesin triggers the formation of an HBHA coiled-coil dimer. 
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Chapter 1: 
A Record of Tuberculosis  
Tuberculosis has been a human plague for centuries.  People infected with Tuberculosis 
would suffer from fevers and severe weight loss contributing to the appearance of being 
consumed from the inside, hence the disease original name, Consumption.  On March 24
th
 1882, 
Robert Koch determined that Mycobacterium tuberculosis was the etiological agent of 
Tuberculosis
1
.  In his work he demonstrated how the disease was transmitted and suggested 
patients be quarantined to prevent further spread of the disease.  Dr. Koch also developed 
methods for staining and growing the mycobacterium, to assist in the study of the disease. 
It is estimated that one third of the world’s population are infected with Mycobacterium 
tuberculosis and there are 9.7 million new active cases of TB (new and relapse) per year
2
.  There 
is resurgence in TB cases in both the developed and developing countries, amongst 
immunocompromised populations, such as those infected with HIV, the elderly and the newly 
born.  Treatment of active Tuberculosis consists of a 6 to 9 month regimen of four anti-microbial 
drugs; rifampin, isoniazid, pyrazinamide and either ethambutol or streptamycin.  These 
combination, of drugs are used to prevent the occurrence of antibiotic resistance.  Multi-drug 
resistance (MDR) and extreme drug resistance (XDR) cases of Tuberculosis are becoming more 
prevalent especially in the developing countries where antibiotics are available without 
prescription and patients are less likely to finish the treatment
3
.  Finding new classes antibiotics,
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 to counteract the growing number of MDR strains of Mycobacterium tuberculosis is 
highly important. 
Disease Progression 
Tuberculosis progresses through several stages of infection.  The droplet nuclei, 
containing the bacterium, are inhaled by the human host allowing the bacilli access to the lungs 
and where infection is initiated.  There is still some debate about the role lung epithelial cells 
play in infection or dissemination of the bacteria, but greater than 90% of the alveolar surface are 
pneumocyte cells, increasing the likelihood of mycobacterial – epithelial cell interactions3.  It is 
here that the alveolar macrophages ingest the bacterium, but since the macrophages are not yet 
activated they are unable to destroy the mycobacterium.  A localized pro-inflammatory response 
is triggered, recruiting mononuclear cells to the site of infection.  The bacteria that escape from 
the non-activated macrophages are phagocytosed by activated macrophages or dendritic cells.    
The mycobacteria interact with many possible receptors on these immune cell surfaces, including 
Toll-like receptors (TLR), nucleotide-binding oligomerization domain (NOD-) like receptors 
(NLRs), C-type lectins (including the mannose receptor [MR]), and other complement, 
scavenger, surfactant protein A (Sp-A), and cholesterol receptors
3
.  The receptor through which 
M. tuberculosis is internalized dictates bacterial treatment.  Interaction with the mannose 
receptor (MR) on the macrophage surface, with lipoarabinomannan (ManLam) structures on the 
bacteria has been shown to prevent maturation of the phagosome with the lysosome
4
.  The 
bacterium is able to survive in a vacuole within the macrophage.  This topic will be further 
discussed in chapter 3.  Phagocytosis via the TLRs is the main extension of the innate immune 
response triggering a pro-inflammatory response. The cellular immune response is linked in 
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particular to the production of IFN - γ.  In most cases, the infection is contained by walling off 
the infected site, forming a granuloma
5
.  In some cases the resistant bacilli can survive inside 
macrophage, and go into a dormant state.  At this point the host is categorized as having latent 
Tb.  The triggering of the dormant state has been studied and one of the proposed mechanisms is 
discussed in chapter 4.  The dormant bacteria can exist in the granuloma for the life of the host 
without the host presenting any symptoms of the disease.   
In those cases where the disease progresses or “awakens”, a region of genes named, 
regions of difference 1 (RD-1) are up-regulated
6
.  RD-1 genes are present in all virulent strains 
of M.tb, but absent from non-pathogenic strains
6
.  Two proteins which assist in mycobacterial 
escape are the early secreted antigenic target (ESAT-6) and culture filtrate protein (CFP-10).  
ESAT-6 has been shown to insert into membranes causing cytolysis of macrophages, 
demonstrating a possible mechanism for escape from the macrophage and release into the extra-
cellular milieu
7
.  Under these circumstances the granuloma center undergoes caseation releasing 
the bacteria into the lung environment.  The infection progresses to other regions of the lung or 
escapes the lung environment.  One method of escape is through host sputum spread by 
productive coughing.  The bacteria can also gain access to the blood stream and disseminate to 
other organ systems.  While the mechanism of dissemination still needs to be elucidated, the 
effect of particular proteins on the process has been studied.  A protein important for 
dissemination from the lungs, heparin binding hemagglutinin adhesin (HBHA), is discussed in 
chapter 2
8
.  Due to its significant impact on public health, the pathogenesis of Mycobacterium 
tuberculosis has been studied for many years.  The focus of this work was on Heparin Binging 
Hemagglutinin Adhesin, Phosphomannomutase (Mt. Manb), and DevS.  These proteins facilitate 
adhesion, dissemination, evasion, and hibernation. 
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Introduction 
When Mycobacterium tuberculosis is inhaled as an aerosol, infection starts in the lung 
environment.  Upon entering the lungs there is a higher likelihood of the mycobacterium 
encountering the lung epithelial cells than an alveolar macrophage.    The mycobacteria need a 
complement of adhesins to interact with this cellular environment along with macrophage 
interactions.  One of the adhesins that Mycobacterium tuberculosis uses to interact with these 
epithelial cells is heparin binding hemagglutinin adhesin (HBHA)
9
.  Genes encoding for HBHA 
are only found in pathogenic strains of mycobacteria, Mycobacterium leprae, Mycobacterium 
tuberculosis, and Mycobacterium avium, not in non-pathogenic strains such as Mycobacterium 
smegmatis
10
.  HBHA is known to interact with the polysaccharide Heparan Sulfate (HS), which 
extends from some epithelial cell receptors
9
.  The role of HBHA in pathogenesis is still debated, 
but its function in dissemination from the lungs has been shown
8
. HBHA has been characterized 
with an ability to agglutiniate red blood cells while also auto-aggregating mycobacteria
9
.  HBHA 
has also been seen to interact with actin molecules within the epithelial cells causing 
rearrangement of the cytoskeleton, which is hypothesized as the mechanism for escape of the 
mycobacteria from the lung environment
11
.  HBHA has also been investigated as a potential 
diagnostic tool of latent tuberculosis
12
, as a possible vaccine
13
, and boosts BCG immunity, 
probably by inducing cytokines that may help with production of Th1 effector-memory 
lymphocytes
14
. 
HBHA is a 199 amino acid (a.a.) long protein found on the surface of Mycobacterium 
tuberculosis.  The adhesin is not evenly distributed among the surface, but is localized to the side 
facing the epithelial cells
15
.  The mechanism by which HBHA is anchored to the surface of the 
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cell is unknown, but there is some thought that the glycosylation on the N-terminal asparagine 
might act as an anchor for the protein.  The saccharide composition is 41.6 % glucose, 17% 
xylose, 10.2 % mannose, arabinose 8.8%, and 9.2% galactose contributing to 2.8 % of the total 
mass of HBHA 
9
.  
There has been much work done on characterizing the oligomerization state of HBHA in 
vivo and in vitro.  Dupres et al. unfolded surface associated HBHA using Atomic Force 
Microscopy (AFM), and concluded that HBHA was a monomer based upon the force of 
unfolding along with the length of the unfolded molecule
15
.  Other work has shown HBHA to be 
an obligate dimer in vitro
9,16
.  It is also predicted from the agglutination data that HBHA exists in 
a higher ordered oligomerization state
9
. From primary sequence analysis, the presence of a 
coiled-coil region present from residues 25 to 108 was detected.  Coiled-coil (CC) motifs are 
known regions of protein – protein interactions.  These regions are characterized by a heptad 
repeat (a-b-c-d-e-f-g), where residues a and d are hydrophobic residues, e and g, are charged 
residue and b, c and f are hydrophilic residues
17
.  Coiled-coils are alpha helices that coil around 
each other, two to seven strands, where the hydrophobic residues are buried in a core and the 
hydrophilic residues are exposed.     
Work done by Delogu and Brennan identified the C-terminal region as the Heparan 
Sulfate binding region of HBHA using heparin as a model ligand
18
.  Heparin is a highly sulfate 
form of HS used as a model in binding studies since it mimics the highly sulfate regions of HS.  
Residues 161 to 199 consist of lysine, alanine, and proline repeats, which present a localized 
positive charge that are complementary to the negatively charge sulfate groups of HS.  Removal 
of this basic region, causes a loss of heparin binding ability of HBHA, while fusion of the C-
terminal region to Maltose Binding Protein (MBP), supports MBP binding to heparin
19
.   
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The primary focus of this work was to understand the contribution of particular regions of 
HBHA on folding, dimerization, and stability. Methods used in the investigation of HBHA were 
circular dichroism (CD) wavelength and temperature studies and analytical ultracentrifugation 
sedimentation equilibrium (AUC-SE). 
Construct Design: 
With no atomistic information concerning the secondary structure of HBHA, software 
was used to give a starting point.  HBHA was put through secondary structure prediction server 
(CCD-NKI) and the resulting data was aligned with previously published coiled-coil predictions 
of HBHA (Figure1) 
20
.  From analysis of the alignment, we chose regions to investigate based 
upon known function and secondary structure prediction.  Residues 161 to 199 were designated 
the HS binding region, while residues 25 to 110 is the coiled-coil region.  The coiled-coil region 
is predicted to end at residue 108, but the alpha helix is also predicted to continue until residue 
110, which is then followed by a predicted gap in structure.  Amino acids between the coiled – 
coil and the HS binding region was designated the linker region, while any residue N-terminal to 
the coiled – coil is part of the N-terminal region.  By breaking the protein down into parts we 
were able to investigate how each section functions.  The list of constructs, used in the in the 
experiments are in Table 1.   
Most constructs started at residue 6 (aspargine) versus native start at residue 1 
(methionine).  The rationale for the alternate start concerned the half-life of the constructs in 
solution.  Constructs that started at residue 6 were more stable, which was important when 
performing analytical ultracentrifugation sedimentation equilibrium techniques that were run for 
three days.  In choosing the construct end residues, we looked at both the end of predicted 
8 
 
secondary structure along with organization of the HBHA.  To test each regions contribution to 
secondary structure, stability, and folding, residues 199 (lysine), 156 (glycine), 111 (serine), 99 
(valine) and 88 (glutamate) were chosen as the C-terminal ends of the constructs.  Along with 
residue 6, residue 20 was used as the N-terminal start so the contributions of the N-terminal 
region could be ascertained. Residue 20 was chosen over residue 24 as the start, because residue 
24 was part of predicted secondary structure.  The resulting data from a construct starting at 24 
could be due to the disruption of the predicted alpha helix versus loss of the N-terminal region.  
Upon further analysis of the secondary structure and coiled-coil alignment a hydrophobic stretch 
of residues 12 to 18 lies within a predicted alpha helix.  In previous work with coiled-coils, it 
was shown that there are motifs that control the formation of coiled-coils, called trigger 
sequences.  As part of our study, we investigated the possibility of the N-terminal helix as a 
trigger sequence.  
Purification: 
  The constructs created with the aforementioned starts and stops along with mutations 
were amplified from M. tuberculosis (strain H37Rv) genome via polymerase chain reaction and 
incorporated into the LIC (ligation independent cloning) vector pMCSG7
21
.  This vector 
incorporates a hexa-his tag at the N-terminus of the HBHA construct linked via tobacco etch 
virus (TEV) protease cleavage site.  L14A, L15A mutants of HBHA 6_199 and 6_111 were 
introduced using site-directed mutagenesis.  Sequence confirmed constructs were inserted into 
pMCSG7 then transformed into chemically competent E. coli BL21 (DE3) AI cells (Invitrogen).  
Transformed cells grew to an optical density of 0.8 in terrific broth (TB) at 37
o
C, with shaking.   
An L-Arabinose solution was added to the growth at a final concentration of 0.2% v/v, and the 
temperature was reduced to 18
o
C for 30 minutes. Protein expression was induced with 0.5 mM 
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IPTG (isopropyl-β-D-thiogalactopyranoside) and cells were allowed to grow for 16 hrs.  Cells 
were then centrifuged at 4500 xg for 30 minutes at 4
o
C.  Pellets were suspended in 50 mL lysis 
buffer (50 mM potassium phosphate, 500 mM NaCl, 5% glycerol, and 20 mM imidazole, pH 
7.4) per 4 liters of culture.  Suspended pellet was frozen drop-wise into a liquid nitrogen bath.  
Pellets were resuspended in the lysis buffer plus protease inhibitor tablets (Roche) and DNase.  
Lysis was achieved using a Branson Sonic Dismembrator at 30% power for 3 cycles of 1 minute 
at 4
o
C.  Constructs were purified over a HisTrap column (GE Healthcare).  The hexa-his affinity 
tag was removed using TEV protease with further purification over a Superdex 200 column (GE 
Healthcare) pre-equilibrated in CD buffer (10 mM Potassium Phosphate pH 7.5, 200 mM KF).  
Fractions containing HBHA were combined and used in the following experiments.   
Circular Dichroism: 
Circular dichroism is a measure of the difference in absorbance of chiral (optically 
active) molecules of plane polarized light consisting of two components, left (counter-clockwise) 
and right (clockwise).  The measurement of the difference:  with 
ellipticity (θ) being the unit of circular dichroism results.  The relationship of ellipticity (θ) to 
absorbance, , with the final CD spectrum plotted as ellipticity as a function of 
wavelength.  We investigate the secondary structure of proteins by viewing the absorbance 
spectra from approximately 240 to 180 nm.  Within this range the absorption is principally from 
the peptide bond, but each secondary structure element generates distinct spectral bands.  Helices 
produce broad negative bands with a center around 222 nm and a negative and positive couplet 
signal around 208 nm and 190 nm, respectively
22
.  The beta-sheet signal is characterized by a 
negative band at 215 nm and a positive band at 195 nm.  If the protein in question contains a 
10 
 
combination of secondary structure then the resultant signal will be an ensemble of the signals.  
Circular dichroism is also sensitive to changes in secondary structure of proteins. When there is a 
loss of secondary structure, a blue shift toward 200 nm is seen in the CD spectrum due to an 
increase in random-coil signal.  Spectral data of target proteins can be analyzed using a variety of 
algorithms and data sets.  Common algorithms are SELCON, CDSSTR, and CONTIN/LL, which 
can be accessed using the online program, Dichroweb 
23
.  Results from data analysis give 
estimates on percentages of the types of secondary structure present in the target protein. 
     HBHA constructs were analyzed by circular dichroism spectroscopy.  Wavelength spectra 
were collected in CD Buffer (10 mM potassium phosphate pH 7.5 and 200 mM potassium 
fluoride) from 260 to 185 nm using an Aviv 62 DS CD Spectrophotometer.  HBHA constructs 
were studied at a concentration of 10 µM in quartz cuvettes (Hellma) with a path length of 0.1 
cm.  Each sample was scanned three times at 20
o
C with a 10 second averaging time.  Spectra 
were averaged and buffer signal subtracted.  Values were converted from ellipticity to mean 
residue ellipticity (MRE) (deg * cm
2
 * dmol
-1
) using equation: 
            (1) 
where θ is ellipticity in mdegs, Mr is the molecular weight divided the number of peptide bonds, 
C is the concentration in g/L and l is the path length in cm. 
HBHA construct stability was analyzed via thermal denaturation by heating the samples 
from 4
o
C to 85
o
C using 1 degree steps with an equilibration time of 2 minutes for each 
temperature step.  Measurements were taken at 222 nm with a 10 second averaging time for each 
degree step within a 0.3 degree dead band.  Transition curves were normalized to fraction folded 
using the equation: 
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            (2) 
where [θ]obs is the observed signal at a given temperature, [θ]u is the value when the peptide is 
unfolded, and [θ]n is the value when the peptide is in its native state.  Reversibility was checked 
by rapid cooling to 25
o
C, followed by a wavelength scan collected from 260 to 185 nm. 
Secondary structure of each construct was further analyzed using three different 
algorithms; CONTIN/LL, CDSSTR, and SELCON.  Two reference sets, set 4 and set 7, 
(appendix A) contained the broadest sampling of proteins at wavelengths pertinent to our studies.  
Wavelength data for each construct, between 240 nm to 190 nm, were uploaded to the 
Dichroweb website
23
.  Each construct data was analyzed by different combinations of algorithm 
with each selected reference set.  Fit integrity was evaluated using normalized root mean square 
deviation (NRMSD) and plotting experimental data versus calculated data.  The product of the 
analysis is percent helix, beta sheet, turn, and unstructured. 
Circular Dichroism Spectroscopy: Wavelength Spectra 
CD spectra from 260 nm to 185 nm for each construct at 10 µM are shown in Figures 2a-
d.  The spectra of HBHA 1_199 and 6_199 were identical, indicating that the truncation of the 
first five residues did not affect the overall structure of the protein (Figure 2a).  The CD spectra 
of constructs 6_156 and 6_111 were then compared to that of 6_199, which showed that the 
secondary structure of HBHA became dominated by alpha helices as the predicted coiled-coil 
region was isolated.  The spectrum from HBHA 6_138 was similar to HBHA 6_156, 
demonstrating that cutting into the linker region had little effect on overall secondary structure 
composition (Figure 2b).  The CD spectra from HBHA 6_88 and HBHA 6_99 were similar to 
one another, and both showed loss of alpha helical secondary structure due to truncation from the 
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C-terminus.  Compared to HBHA 6_111 (Figure 2b), the minima at 208 nm and 222 nm are 
more positive and the maximum at 190 nm is more negative.  These transitions were 
accompanied by a blue shift of the minimum observed near 208 nm; together, these data support 
the conclusion alpha helical secondary structure is lost in these constructs relative to longer 
version of HBHA examined.   
Previous published work had shown that truncation of the first 24 residues of HBHA 
results in a loss of secondary structure
16
.  Therefore, a construct starting at residue 20 (alanine) 
was designed, since a truncation at residue 25 is within a predicted helix and close to the 
predicted coiled-coil start.  The introduction of the N-terminal truncation caused a loss of 
secondary structure when compared to 6_199, as indicated by the observed shift in the minimum 
at 208 nm to 200 nm and a loss of CD signal intensity at 222 nm and 190 nm (Figure 2c).  At the 
N-terminus of HBHA, there is a marked stretch of hydrophobic residues (see Fig. 1).  Two 
leucines within this region, leucines 14 and 15, were mutated to alanines using site-directed 
mutagenesis with the goal of disrupting the coiled-coil. The mutation of leucines 14 and 15 to 
alanines had a similar disruptive effect on the secondary structure (Figure 2c).  Thus, altering the 
N-terminal region lying outside the predicted coiled-coil has adverse effects on the alpha helical 
secondary structure of HBHA 
The leucine mutations were then incorporated into the most alpha helical construct, 
HBHA 6_111.  However, following TEV protease cleavage during purification of the construct, 
the protein formed a soluble aggregate as determined by size exclusion chromatography and 
dynamic light scattering (data not shown).  This aggregate was examined on the CD 
spectrophotometer along with HBHA 6_111 and HBHA 20_199 (Figure 2d.).  We observed a 
total loss of secondary structure signal when the leucine mutations were introduced in the 6_111 
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construct relative to 6_199 due to aggregate state of construct.  Taken together, these data 
demonstrate that the primary structural component for HBHA is the alpha helix and the 
maintenance of this structure is insensitive to C-terminal truncations up to the predicted end of 
the coiled-coil at residue 111, but highly sensitive to mutation or truncations within the N-
terminus leading up to residue 20. 
Dichroweb Output 
Decovolution software has been shown to work best for helical proteins
23
.  Each 
constructs secondary structure content were evaluated using CONTIN/LL, SELCCON, and 
CDSSTR along with reference sets ref 4 and ref 7 (Appendix A).  Using various software and 
reference sets secondary structure values were generated for each construct.      Fitting results are 
listed in Table 2.  Values are estimates of secondary structure present in the sample, not a precise 
quantification of the structure. The most alpha helical signal was obtain from HBHA 6_111, with 
HBHA 20_199 and HBHA 6_199 L14A L15A having the least alpha helical content.  As HBHA 
is truncated from the C-terminus, there is an increase in alpha helical structure until we cut into 
the predicted coiled - coil (HBHA 6_88).  
Thermal Denaturation 
The CD signal at 222 nm is generally accepted as an accurate measure of the alpha 
helical content of a protein and because HBHA is composed of primarily alpha helices, 222 nm 
was considered an appropriate measure of HBHA folding and stability
24
.  The constructs 6_199, 
6_156, and 6_111 were analyzed along with the full length construct, HBHA 1_199 (Figure 3a).  
Melting temperatures (Tm) were determined and are listed in Table 3.  As reported above, the 
signal generated by HBHA 1_199 was similar to that of 6_199 (Figure 3a).  No difference in 
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protein stability was detected upon the removal of the HS binding domain (e.g., see the data for 
HBHA 6_156 in Figure 3a).  However, the Tm began to decrease once the full linker region was 
removed from the HBHA construct (e.g., HBHA 6_111 in Fig. 3a).  Truncating the linker region 
increased the alpha helical secondary structure and had an effect on stability as seen by a 
decrease in Tm (Fig. 3b).  Once the predicted coiled-coil region was disrupted, significant 
reductions in Tm were observed (Table 3).  It was noted that when transitioning from 60
o
C to 
40
o
C the data for HBHA 6_88 were noisier relative to the other constructs (Figure 3b), likely due 
to a more disordered nature of the construct. 
The change in Tm as a function of peptide length is plotted in figure 3c.  As residues are 
truncated from the C-terminus, only a small decrease in the Tm of the HBHA constructs is 
observed.  However, as we disrupted the predicted coiled-coil region, a more significant decrease 
in Tm is observed (see also Table 3).  The limited stability of constructs HBHA 20_199, HBHA 
6_199 L14A L15A, and HBHA 6_111 L14A L15A did not allow for successful analysis of these 
proteins by thermal denaturation.  Collectively, though, these data indicate that disrupting the 
coiled-coil domain from the C-terminus weakens the fold of the HBHA dimer. 
Analytical Ultracentrifugation Sedimentation Equilibrium: 
Sedimentation equilibrium experiments were performed on HBHA constructs at 20° C in 
a Beckman XL-I analytical ultracentrifuge using 6-sector cells and an An50Ti rotor. Samples at 
three different concentrations (20, 10, 5 µM) were spun at three velocities (3.22 x10
4
, 7.24 x10
4
, 
and 1.30 x10
5
 xg) until equilibrium was reached. Absorbance was monitored every two hours at 
230nm and 280 nm. Absorbance offset values were determined using the meniscus depletion 
method by overspeeding the samples at 1.63 x10
5
 xg for 6 hours.  The program SEDNTERP 
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(John Philo, Thousand Oaks, Ca and RASMB) was used to calculate solvent density and 
viscosity along with molecular mass and partial specific volume for each HBHA construct.  Data 
sets were initially analyzed using SEDFIT 
25
 in order to generate the proper file type for analysis 
with SEDPHAT
26
.  Using SEDPHAT, a species analysis model was applied to each construct 
data set to determine the solution make up for each construct.  Standard curves for each HBHA 
construct were generated at 230 nm in order to derive the extinction coefficients using the Beer-
Lambert law.  Data for each construct was also plotted using the equation: 
                                                                                                            (3) 
where Cr is the concentration at radius, r, Cr0 is the concentration at the reference point, M is the 
molecular weight,  is the partial specific volume of the molecule, ρ is the density of the 
solution, ω is the radial velocity of the experiment, R is the gas constant, T is the temperature of 
the experiment (K), r is radius and r0 is the reference radius.  The resulting plot is linear if the 
molecule population is monodisperse, while a curved lined indicates the polydispersity of the 
sample.  The slope of the line is proportional to the mass of a single species. 
Because HBHA may form an elongated dimer, we employed analytical 
ultracentrifugation sedimentation equilibrium (AUC-SE) to obtain accurate masses of HBHA 
constructs due to the shape independence of this technique
27
. The full length construct of HBHA 
1_199 was compared to HBHA 6_199 to confirm that the deletion of the first 5 residues had no 
effect on oligomerization (Figures 4a – f). Regional constructs HBHA 6_156 and HBHA 6_111 
were examined at 3 different concentrations, with the 10 µM traces being displayed in Figures 
5a, b.  These constructs demonstrated no loss of dimerization with truncations from the C-
terminus.  It further appears that the gain of secondary structure when compared to HBHA 6_199 
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was not due to a change in oligomeric state (Table 4).  With construct 6_88 (Figure 5c), the 
HBHA molecule was truncated into the predicted coiled-coil region.  This construct was treated 
the same as previous constructs and also was found to be a dimer in solution (Table 4).  N-
terminal truncation and leucine mutant constructs were treated as previous constructs with the 10 
µM traces shown in Figure 6a (HBHA 20_199) and Figure 6b (HBHA 6_199 L14A L15A), 
along with the corresponding residuals.  These two constructs were calculated to have the mass 
of a monomer (Table 4).  Indeed, at all three concentrations, HBHA 20_199 and HBHA 6_199 
L14A L15A, exist as a monomer in solution.  Together with the CD spectra, these data indicate a 
link between a major loss in secondary structure signal and the conversion to monomer in 
solution.  In contrast, constructs with alpha helical characteristics existed as dimers in solution. 
Constructs were also plotted using equation 3, described in the methods.  The resulting 
plots for each construct were linear indicating all samples are a single species in solution (Figure 
7).  The molecular weights of each macromolecules influence the slope of the line, resulting in 
the largest molecular weight construct, HBHA 1_199, having the greatest slope and the smallest 
molecular weight, HBHA 6_88, construct have the smallest slope. The resultant molecular 
weights from these plots corroborated the molecular weights achieve using the fitting software. 
Crystallization Trials: 
Constructs HBHA 6_199, HBHA 6_156, and HBHA 6_111 were also used to set-up 
crystallization trials for HBHA.  Constructs were exchanged in 20 mM HEPES pH. 7.0 and 200 
mM NaCl (crystallization buffer), through either dialysis or buffer exchange column.  
Concentrations of 10 mg/ mL for HBHA 6_199, and 20 mg/ mL for HBHA 6_156 and 6_111 
were determined using the Pre-Screen (Qiagen).  Trials were screened versus a myriad of sparse 
matrix, single component, polyethylene glycol (PEG), and pH screens (For a full list of screens 
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see Appendix B).  None of these crystal trials resulted in crystallization of HBHA.  A vector was 
built (see chapter 5) based upon published data to aid in crystallization.  Previous work 
expressing a target protein fused with a previously crystallized protein was seen to yield crystals 
where there was previously none
28
.  The cysteine protease domain of the Multifunctional 
Autoprocessing Repeats-in-Toxin (MARTX) protein (CPD) was chosen as a fusion partner for 
our target protein.  The three previously mentioned HBHA constructs were expressed C-
terminally fused to CPD along with a hexa-his tag C-terminal to the CPD.  Expression and 
purification were conducted the same as previously mentioned with the exception of the TEV 
protease step.  
Purified HBHA-fusion constructs were concentrated to previously mentioned amounts.  
Nickel purified samples were loaded over the Supdexdex200 size exclusion chromatography 
column and samples where collected.  The trace of the purification of HBHA 6_111 fusion, 
(Figure 9a) displayed peaks of molecular weights corresponding to CPD alone and HBHA 6_111 
dimer (~24 kDa).  Figure 10a is an SDS-PAGE gel of the fractions (83.33 mLs and 92.84 mLs) 
of HBHA 6_111 + CPD untreated with phytic acid, while figure 9b has fractions from previously 
purified HBHA 6_111 + CPD treated with phytic acid.  The bands present in both gels are 
similar demonstrating that the HBHA 6_111 + CPD autocleaved without the presence of phytic 
acid.  When phytic acid is added to CPD, the N-terminal region of the protein becomes more 
rigid, positioning the catalytic cysteine for attack.  The dimerization of HBHA 6_111 could 
possibly be performing the same role as phytic acid allowing the protein to cleave.  To maintain 
the fusion, we tested multiple cysteine protease inhibitors with N-ethylmaleimide irreversibly 
inhibiting CPD.    Each construct was treated with protease inhibitor and purified over the 
Superdex200 in crystallization buffer.  A trace of HBHA 6_111 fusion treated with N-
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ethylmaleimide (Figure 9b) displays peaks expected of the HBHA 6_111 fusion dimer.  
Fractions from the 75.26 mL peak, which corresponds to the fusion dimer (~71 kDa) were run on 
a SDS - PAGE gel (Figure 10c).  All fractions show the presence of a stable fusion protein with a 
molecular weight of 35 kDa.  Crystallization trials were setup at a range of concentrations from 
10 to 20 mg/ mL of the HBHA 6_111 fusion protein.   
Discussion: 
Heparin Binding Hemagglutinin Adhesin is a surface protein of Mycobacterium 
tuberculosis employed for adhesion to epithelial cells; in addition, HBHA has been observed to 
aggregate and agglutinate in solution
29
.  Recent studies have shown that HBHA exists in a 
dimeric state in a range of concentrations in solution.  This dimer was the focus of our work.  
With no atomistic model available for HBHA, we employed secondary structure predictions to 
guide the design of constructs.  These data were overlaid with the primary sequence along with 
the published coiled-coil prediction (Fig. 1).  From the schematic of HBHA, we divided the 
protein into four regions: N-terminal region (blue), predicted coiled-coil (red), linker region 
(green) and the Heparin Sulfate binding region (orange).  Constructs were designed to test the 
role each region may have in dimerization.  Most constructs were started at residue 6, aparagine 
(N) versus the starting methionine.  Two factors led to the decision to start at residue 6: first, the 
constructs that began with this N expressed well; second, they exhibited an improved half-life in 
solution, which was important for subsequent analytical ultracentrifugation studies. However, as 
shown in our data, constructs that began with either residue 1 or 6 behaved similarly throughout 
our biophysical characterizations.   
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Constructs 6_199, 6_156, 6_111, and 20_199 were initially characterized by circular 
dichroism spectroscopy.  The trace for HBHA 6_199 appeared similar to previously published 
data
27
.  However, as we started truncating HBHA from the C-terminus, an increase in the alpha 
helical signal was observed, with HBHA 6_111 being the most alpha helical (Fig. 2a).  These 
data suggest that, in vitro, a majority of the residues after 111 are either disordered or in a non-
alpha helical conformation, and that a vast proportion of residues 1 through 111 are in an alpha 
helical state.   
  HBHA 6_199, HBHA 6_156, and HBHA 6_111 were analyzed by AUC-SE and all 
were determined to have a buoyant mass of a corresponding dimer (Table 4).    Unlike the 
previous constructs, HBHA 20_199 had a decrease in alpha helical signal and the protein 
adopted a more random coil conformation seen by a shifting minimum from 208 to 200 nm.  
HBHA 20_199 was further characterized by AUC-SE (Fig. 6a and 7) and the resultant buoyant 
mass was equivalent to a monomer (Table 4).  These AUC-SE and CD data indicate a link 
between protein folding and dimerization with the N-terminal region being responsible for 
forming and maintaining the HBHA dimer.  HBHA 6_199, HBHA 6_156, and HBHA 6_111 all 
contain the N-terminal region and have alpha helical CD spectra.  Removal of the N-terminus 
causes the loss of a characteristic alpha helical signal.   
Mutation of Leu-14 and Leu-15 to alanines resulted in a construct that produced a similar 
CD spectrum as HBHA 20_199.  And, like HBHA 20_199, this construct was a monomer in 
solution.    These data implicate the N-terminal region, in particular the predicted helix from 
residue 7 to 18 (Fig. 1), in dimer formation and folding.  However, while the N-terminal region 
is important for formation of the dimer and folding of the protein, the coiled-coil is still 
important for the maintenance of the dimer.  When residues are eliminated from the C-terminus 
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of the coiled-coil, there is weakening of protein stability.  From the thermal denaturation 
experiments, HBHA 6_88 is not as stable when compared to either HBHA 6_111 or HBHA 
6_156 (Fig. 3b).  These observations support the conclusion that while contacts present in the 
coiled-coil are important for stability and preservation of the fold, it is N-terminal region that 
triggers folding and dimerization.   
Thus, we propose that the first helix acts as a trigger sequence (Figure 8) for HBHA 
dimerization.  Trigger sequences have been identified in other coiled-coils, where they have been 
shown to control folding and oligomerization
30
. HBHA is expressed predominantly on the 
Mycobacterium tuberculosis surface facing epithelial cells
15
.  The heparan sulfate ligand 
recognized by HBHA is presented on epithelial cells in grouped brush structures
31
.  Thus, we 
further propose that the HBHA dimer triggered by the N-terminal residues 6 - 19 of the protein 
serves to increase the local concentration of this adhesin such that optimal contacts with heparan 
sulfate brush structure can be formed. Such contacts would be expected to be critical to the 
initiation of pathogenesis by Mycobacterium tuberculosis. 
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Figure Legends 
1. Figure 1: Diagram of the primary sequence for HBHA aligned with a secondary 
structure prediction and the coiled-coil prediction.    Sequence is separated into 4 
regions: blue – N-terminus, red – predicted coiled-coil, green – linker, and orange – 
heparin binding region.  Starts and ends to constructs are shown by orange and black 
hashes respectively.  AA represents the amino acid at the residue number above, while 
Sec Pred is the secondary structure predicted for that amino acid.  Finally if the residue is 
part of the predicted coiled-coil a “c” is listed in the Coiled - Coil row. 
 
2. Figure 2:  Far UV-CD spectra of regional HBHA constructs at 10 µM:   (A) (●) 
6_199, (▲) 6_156, (♦) 6_111, and (■) 1_199. (B) (■) 6_156, (▲) 6_138, (♦) 6_111, and 
(●) 6_88. (C) (●) 6_199, (▼) 20_199, and (■) 6_199 L14A L15A. (D) (♦) 6_111, (▼) 
20_199, and (●) 6_111 L14AL15A 
 
 
3. Figure 3:  Thermal denaturation of HBHA constructs monitored at 222 nm.   (A) 
Constructs (●) 6_199, (■) 1_199, (▲) 6_156, and (♦) 6_111 were all at 10 µM.  (B) 
Constructs (▲) 6_156, (■) 6_138, (♦) 6_111, and (●) 6_88 were all at 10 µM.  (C) Plot 
of construct size (number of amino acids) versus calculated melting temperature 
 
 
4. Figure 4:  Absorbance detected analytical ultracentrifugation – sedimentation 
equilibrium traces with residual plots.    Plot of AUC-SE for HBHA 1_199 at 3 
concentrations (A) 5 µM, (B) 10 µM, and (C) 20 µM at three velocities (■)3.22 x104 xg, 
(▲)7.24 x104 xg and (●)1.30 x105 xg  D – E: Plot of AUC-SE for HBHA 6_199 at 3 
concentrations (D) 5 µM, (E) 10 µM, and (F) 20 µM at three velocities (■)3.22 x104 xg, 
(▲)7.24 x104 xg and (●)1.30 x105 xg  
 
 
5. Figure 5:  Absorbance detected analytical ultracentrifugation – sedimentation 
equilibrium traces with residual plots.     HBHA constructs at 10 µM (A) HBHA 
6_156, (B) HBHA 6_111, and (C) HBHA 6_88 at three velocities (■) 3.22 x104 xg, (▲) 
7.24 x10
4
 xg and (●) 1.30 x105 xg 
 
 
6. Figure 6:  Absorbance detected analytical ultracentrifugation – sedimentation 
equilibrium traces with residual plots.    HBHA constructs at 10 µM (A) HBHA 
20_199 and (B) HBHA 6_199 L14A L15A at three velocities (■) 3.22 x104 xg, (▲)7.24 
x10
4
 xg and (●)1.30 x105 xg 
 
7. Figure 7:  7.24 x104 xg AUC Data of HBHA constructs plotted as a relation of 
molecular weight.     (●) HBHA 1_199, (■) HBHA 6_199, (▲) HBHA 6_156, (▼) 
HBHA 6_111, (♦) HBHA 6_88, ( ) HBHA 6_199 L14A L15A, and (.) HBHA 20_199 
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8. Figure 8: Schematic of HBHA Model. 
 
9. Figure 9: Size exclusion chromatography traces of HBHA 6_111.      (A) Purification 
of HBHA 6_111 + CPD without N – ethylmaleimide  (B) Purification of HBHA 6_111 
with N – ethylmaleimide 
 
10. Figure 10: SDS -PAGE gel of HBHA 6_111 + CPD.      (A) lane 1 fermentas ladder, 
lane 2 – 83.33 mLs peak, lane 3 – 92.84 mLs peak. (B) lane 1 – phytic acid treated 
sample, lane 2 – imidazole eluted fraction, lane 3 – Bio-Rad unstained ladder. (C) Lane 1 
– Bio-Rad unstained ladder, Lanes (2-9) fractions A8 – B10. 
  
 
Chapter 3: 
 Function of Mt  Manb: A Mycobacterial Phosphomannomutase 
Introduction 
The pathogenic pathway of Mycobacterium tuberculosis involves invading and 
parasitizing the host alveolar macrophages.  One possible interaction between the macrophage 
and mycobacteria involves the C-type lectin mannose receptor and the mannose-capped 
lipoarabinomannan (ManLam) molecules on the respective cell surfaces
32
.  The C-type lectin 
mannose receptor (MR) recognizes carbohydrates on the surface of microorganisms
33
.  Binding 
via the MR triggers engulfment without necessarily causing a pro-inflammatory response
34
.  
Phagocytosis, via the C-lectin receptor, prevents phagosome maturation resulting from the 
inhibition of calcium ion production in the macrophage cytosol
35
.  Downstream processes that 
recruit early endosome antigen 1 to the phagosome are inhibited preventing the fusion of the 
phagosome to the endosomal-lysosomal vesicles allowing the mycobacterium to exist within the 
vacuole
32
.   
The ManLam molecule, which binds to the Mannose receptor, is built off a lipomannan 
backbone (Figure 11).  The lipomannan (LM) chain is composed of an alpha 16 Mannose 
phosphate scaffold anchored to phosphatidlyinositol backbone.  The further addition of arabinose 
branch structures extends the complex molecule further away from the cell surface.  Finally the 
lipoarabinomannan (LAM) structure is capped by mannose polysaccharides.  Synthesis of the
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 nature of ManLam structures are still being investigated, but the mannose donor 
molecule is exclusively guanosine diphosphate mannose (GDP-mannose)
36
.  The synthesis of the 
GDP-Mannose molecule happens through a series of enzymatic reactions (Figure 12).  Mannose 
– 6 - phosphate enters the pathway through two possible paths.  The first involves mannose 
uptake from the extracellular environment and conversion to mannose – 6 – phosphate (M6P) via 
a hexokinase.  The second path requires the conversion of glucose-1-phosphate to mannose-6-
phosphate by means of several enzymes, including isomerases and mutases
37
.  The mannose - 6 - 
phosphate is then converted into mannose – 1 – phosphate (M1P) via a phosphomannomutase.  
Mannose-1-P is further process using the enzyme GDP-mannose pyrophosphorylase generating 
the donor molecule, GDP-mannose.  Both pathways converge at the mannose 6 phosphate to 
mannose 1 phosphate, which is facilitated by phosphomannomutase, MtManb (Rv3257c)
37
. 
Background 
  Mt. Manb is a member of the phosphohexomutases, which interconvert M6P to M1P or 
glucose – 6 – phosphate to glucose – 1- phosphate.  Members of the phosphohexomutase family 
use catalytic serine residues to perform their function and require magnesium for catalysis to 
occur
38
.  Prior to substrate binding, the catalytic serine is phosphorylated by an unknown 
mechanism.    In vitro experiments, a 1,6 - bis-phosphate hexose sugar is used to “prime” the 
reaction
39
.  Upon substrate binding (e.g. M6P) the phosphorylated serine donates the phosphate 
group generating a 1,6 - bis-phosphate sugar intermediate.  The intermediate sugar is then rotated 
180 degrees within the binding pocket reorienting the 6 position phosphate near the catalytic 
serine
39
.  The serine residue removes the 6 – phosphate from the sugar intermediate leaving only 
the 1 – phosphate.  The product is released and the catalytic serine is again phosphorylated and 
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ready to perform another cycle. The focus of this work was to obtain the x-ray crystal structure 
of Mtmanb along with designing a high throughput assay to test potential inhibitors.  Inhibition 
of Mtmanb would prevent synthesis of ManLam molecules on the surface of pathogenic 
mycobacterium preventing macrophage phagocytosis via the mannose receptors, which would 
subsequently allow for phagosome – lysosome maturation and bacterial death.  
The current activity assay for phosphohexomutases involves coupling reactions with 
several enzymes (Figure 13) where the ultimate signal is the change in O.D.340 due to the 
conversion of NADP
+
 to NADPH.  M1P is converted to M6P by phosphomannomutase followed 
by the conversion to fructose – 6 – phosphate (F6P) by phosphomannose isomerase.  F6P is then 
converted to G6P by phosphoglucose isomerase, and finally G6P is converted to 6-
phosphogluconate while NADP
+
 is reduced to NADPH.  Due to potential inhibition of ancillary 
enzymes, this assay is not optimized for screening inhibitor libraries via high throughput 
methods.  Each protein in the coupled assay would have to be screened individually for 
inhibition.  A new assay we are proposing has one coupling enzyme, Mannose-6-P reductase, 
which uses NADPH to reduce M6P, and in the process it, NADPH, is converted to NADP
+
.  
Like the established assay, the change in OD340 is being measured.  The reduction in coupling 
proteins should be a benefit to high throughput screening. 
Construct Design and Protein Expression 
The gene for Mtmanb (Rv3257c) was cloned out of H37Rv genomic DNA and inserted 
into pUC19 using polymerase chain reaction and ligation reactions.  Based on previously 
crystallized homologs listed in the Protein Data Bank (PDB)
40
 and secondary structure 
predictions aligned with domain function, the full length protein was the only construct designed 
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and cloned into the bacterial expression vector pMCSG7
21
.  Cloning into the expression vector 
was discussed in chapter 2 and sequence verified genes were transformed into BL21 (DE3) cells 
and BL21 (DE3) – RIPL cells due to the presence of rare codon clustering in the DNA sequence.  
Test expression studies were performed using TB media for overnight and LB media in 4 hour 
inductions.  Cells were lysed and protein expression was verified via SDS-PAGE gel.  Protein 
was purified over nickel sepharose column (GE healthcare) and his-tag was removed using TEV 
protease overnight dialyzing against TEV buffer (20 mM Tris-HCl pH 8.0, 100 mM NaCl, 1 mM 
DTT) at 10
o
C.  The cleavage reaction was re-passed over a nickel column removing the histidine 
tag and any uncleaved material.  Cleaved sample was collected and concentrated to a volume < 
5mL.  Concentrated sample was injected over a Superdex200 size exclusion column (GE 
Healthcare) (Figure 14).  Protein from the 81 mL peak were combined and used for 
crystallization trials in 20 mM Tris – HCl pH 8.0 100 mM NaCl. 
Mannose – 6 – Phosphate Reductase 
The Arabidopsis thaliana gene for mannose – 6 – phosphate redutase (M6PR) was 
ordered from the Arabidopsis Biological Resource Center (ABRC) at Ohio State.  The gene 
came inserted into pUC18 and transformed into DH5.  Using sterile technique, an innoculum 
loop was used to streak the bacteria on a LB + Ampicillin plate.  The plate was grown at 37
o
C 
was grown overnight.  Colonies from were used to inoculate 6 mL LB + Amp cultures, grown 
overnight.  DNA was harvested using Qiagen® miniprep kit. The full length M6PR gene was 
cloned out of pUC18 using PCR.  The gene was then inserted into pMCSG7 using LIC method.  
Sequence verified vectors were transformed in Bl21 (DE3) competent cells for expression.  1 
Liter cultures were grown to an O.D.600 of 0.8.  A final concentration of 0.75 mM IPTG was used 
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to induce expression of M6PR.  Cells were harvested after 4 hrs and were pelleted at 4500 xg.  
M6PR was purified following the same protocol used for His-Lic Mtmanb. 
Discussion 
Rv3257c is a phosphomannomutase used in the production of GDP-mannose donor 
molecule for synthesis of the ManLam structures on the surface of Mycobacterium tuberculosis.  
The interaction of the ManLam with mannose receptors on macrophages has been shown to 
inhibit phagosome – lysosome maturation37.  Inhibition of ManLam synthesis would allow the 
macrophages to ingest the bacterium via another receptor allowing for proper disposal of the 
invading microbe.  Our goal for the project was to get the three dimensional crystal structure of 
Rv3257c and develop a high throughput method for screening inhibitors. 
From previously crystallized homologs (PDB #: 2FKF, 1P5D, and 1K2Y) and secondary 
structure prediction the full length construct was chosen as the target.  The classical PGM_PMM 
domains extend from residue 9 to residue 464.  Prior to setting up Mtmanb crystals trials, a pre-
screen technique was used to determine a concentration range for the trials
41
.  Our concentration 
range for crystallization was 10 mg/ mL to 17 mg/ mL.  Previously crystallized homologs were 
crystallized at this concentration range
38
.  Crystallization trials were setup against screen listed in 
Appendix B.  None of these conditions yielded diffraction quality crystals.  Conditions similar to 
those setup by Regni et al.
38
 were also tried with no crystal formation. 
When comparing Mtmanb sequence to 2FKF the sequences were 35.6 % identical and a 
52% homology.  Using the PHYRE server a three dimensional model was generated for Mtmanb 
using it homologs as references
42
.  The three dimensional model from Mtmanb and three 
dimensional structure of 2FKF can be seen in figure 16 a,b, and c
40
.  The alignment of the 2FKF 
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structure and the Mtmanb model, shows similarities in overall fold.  Next we generated the 
surface charge potentials of the 2FKF structure and the Mtmanb model (Figure 17 a, b) using 
PyMOL software
43
.  Surface charge potentials are based on amino acids present in the protein at 
particular area where regions of negative charge are colored red and regions of positive charge 
are blue.  The mask generated from the surface charge potentials are based on Poisson - 
Boltzman calculations and are meant to be a generalized representation of the charged surface of 
the protein.  The charge masks help demonstrate the differences between the two proteins, even 
with high homology and identity.  The surface charge difference may have led to failure of 
crystallization.  In figure 17 a, b, the two surface masks have matched orientation.  The regions 
of the protein surround by the yellow box mark the surface where symmetry mates interact 
(crystal contacts).  The insufficient formation of intermolecular contacts is one of the main 
barriers to stable lattice formation
44
.  In figure 17b, 2FKF symmetry mate contacts a region of 
positive charge, while the same region is negatively charged in the model of Mtmanb.    If we 
rotate each structure clockwise 90
o
 (Figure 18), another region of symmetry mate contact is 
highlighted by the yellow box in figure 18b.  Again there is a difference in charge present at the 
site of contact.  Two regions of possible intermolecular contact between symmetry mates are 
possibly not present in a Mtmanb lattice.  The difference in surface charge distribution might be 
one of the reasons for a breakdown in the crystallization of Mtmanb. 
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Figure Legends 
11. Figure 11: Structure and Biosynthesis of ManLam 
 
 
12. Figure 12: GDP-mannose Synthesis Pathway 
 
 
13. Figure 13: Phosphohexomutase Coupled Assay Schematic 
 
 
14. Figure 14: SEC200 Purification of Rv3257c.     Aliquots were taken during each step in 
Rv3257c purification.  Lane 1 – Protein ladder, 2 lysate, 3 flow through, 4 Wash, 5 
elution, 6 – 7 TEV fraction elution, 8 TEV fraction pre flow through, 9 flow through 
TEV fraction (used for crystallization)  
 
 
15. Figure 15: Ribbon Diagrams of Mt Man Model and PDB Structure 2FKF. 
 
16. Figure 16: Charge potentials diagrams from Mtmanb model and 2FkF from the 
PDB 
 
17. Figure 17: Charge potential diagrams from Mtmanb model and 2fkf rotated 90 
degrees about the z-axis. 
  
 
 
 
Chapter 4: 
Two Component Sensor Histidine Kinase (DevS) 
Introduction  
The treatment for Tuberculosis is multi-month regimen of antimicrobials that if 
improperly administered allows the mycobacterium to become resistant the treatment.  
Maintaining the regimen in poor or developing countries takes great effort due to limited access 
to physicians to monitor patient’s progress and money for treatment.  The cause for an extended 
therapy is due to Mycobacterium tuberculsosis’ ability to undergo metabolic transformation to a 
dormant state or in a state of non-replicating persistence (NRP) within granuloma’s45.  Current 
antibiotic treatment is only effective against active mycobacteria not bacteria in NRP, so a 
constant level of antimicrobials needs to be present to ensure complete mycobacterial death.  
NRP has been shown to be triggered by hypoxia or the presence of nitric oxide (NO), which is 
produced in macrophages via inducible Nitric Oxide Synthase (iNOS)
46
.  NRP is induced by up-
regulating 48 genes under the control of the DevSR two-component system
47
. 
Two Component System 
Two component systems are composed of a histidine kinase (HK) and a response 
regulator (RR) used to process the signal in response to some external stimuli.  DevS is a sensor 
histidine kinase that reacts to the change in the macrophage environment.  Once the appropriate 
conditions are present, the protein undergoes autophosphorylation at His 395
45
.  The phosphate is
31 
 
 transferred to aspartate 54 (Asp 54) of the RR, DevR, using Mg
2+
 as a co-factor
48
.  DevR 
then triggers up-regulation of dormancy genes, guarding the mycobacterium from the 
macrophage/ granuloma environment along with protecting the bacterium from Tuberculosis 
treatment
49
.  To increase the efficacy of the current treatment, the addition of an anti-dormancy 
compound should be included in the treatment regime.   
There are approximately 11 different two component systems characterized in 
Mycobacterium tuberculosis, whose functions range from chemotaxis to osmoregulation 
50
.  In a 
comparison of avirulent and virulent strains of Mycobacterium tuberculosis, the DevS – DevR 
system (differentially expressed in the virulent strain) was the shown to be up-regulated in 
virulent strains  during infection
50
.  Recent work by Voskuil et al., suggested that the redox state 
is the triggering event and they demonstrate a path by which the respiratory state of the bacteria 
can be linked to DevS activation 
51
.  The focus of this work was to the sensor histidine kinase, 
DevS.   
Background 
DevS is a 578 amino acid long protein compartmentalized into four distinct regions, 
starting from the N-terminus; GAF (cGMP-specific phosphodiesterases, adenylyl cyclases and 
FhlA) A (residues 63 to 200), GAF B (residues 231 to 369), histidine kinase (residues 386 to 
452), and HSP (heat shock protein) - 90-like ATPase (residues 488 to 577).  These domains work 
in concert to process the dormancy signal from outside stimuli to expression of proteins such as 
alpha crystallin
52
.  The GAF domains (A and B) are commonly found in tandem in most proteins, 
where one function’s as a small molecule regulatory domain and the other can either have similar 
function or act as a dimerization domain
53
.  The most common cofactors bound by these domains 
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are cyclic nucleotides and no other GAF domains have been shown to bind heme
53
.  In contrast 
the PAS (period circadian, aryl hydrocarbon receptor nuclear translocator protein, single-minded 
protein) domains bind to heme as a co-factor
53
.   
From work done by Sardiwal et al., it was determined that the first GAF domain, GAF A, 
binds to heme while the function of the second GAF domain, GAF B is undetermined
54
. GAF 
domains and PAS domains are structurally similar, but the sequences are unrelated and each 
domain binds heme in different orientations
55
.  GAF A binds the beta-Heme perpendicular to the 
beta-strands while PAS domains bind heme parallel to the beta-strands (Figure 19 a, b)
55
.  It has 
been shown that histidine 149 (H149) is important in heme binding in the GAF A domain.  When 
the residue is mutated to alanine (H149A) the domain is no longer capable of binding heme
54
.  
NO binding to the iron center or the absence of diatomic oxygen, triggers 
autophosphorylation
56
.  Yukl et al. describe tyrosine 171 (Y171), hydrogen bonding to the bound 
O2 molecule, bound to the iron, being the inactive form of the molecule
56
.  Upon NO binding or 
O2 displacement, Y171 moves out of position and potentially interacts with E87 as part of a 
hydrogen binding network
55
.  Mutation of Y171 to phenylalanine did not cause the protein to 
become constitutively active, but was incapable of activity, demonstrating the relationship 
between Y171 and activity
55
.  The crystal structure of GAF A domain has been solved in several 
redox states and bound ligands.  In none of these structures were there any large conformational 
changes that would hint to the mechanism of autophosphorylation.  The authors thought this 
might be due to the constraints of crystal packing
55
.   
The structure of the GAF B domain from Mycobacterium smegmatis DevS has also been 
solved, but functional questions still remain
57
.  Other members of the GAF superfamily use the 
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second GAF domain as either a small molecule binding pocket or dimerization domain, but none 
of these functions are present in GAF B
57
.  GAF B does not bind to any tested ligand, nor has 
DevS been seen as a dimer in vitro.  Some work has shown that GAF B increases the specificity 
of O2 bound to heme, as the stabilizing molecule for the hydrogen bonding network 
58
.  How this 
signal is transferred to the kinase domain is still unknown and it is possible that the GAF B 
domain acts as a transducer for the signal from GAF A to the histidine kinase/ ATPase regions of 
DevS. 
The C-terminal region of DevS consist of the histidine kinase (HK) and ATPase domain.  
The donor phosphate comes from the hydrolysis of ATP (adenosine-5'-triphosphate) by the 
ATPase (residues 488 to 577) relieving the gamma phosphate.  The phosphate is then passed to 
the RR, DevR, causing up regulation of the dormancy regulon.  The focus of this work was to 
crystallize the four domains of DEVS in both the active and inactive forms to elucidate how 
hypoxia or NO binding triggers auto-phosphorylation and subsequently dormancy. 
Construct Design, Protein Expression and Purification 
Designing constructs for DevS proceeded as mentioned in chapter 2 with initial analysis 
of secondary structure and domain organization.  The gene for DevS (Rv3132c) was cloned from 
M. tuberculsosis H37Rv genomic DNA using PCR amplification into pUC19 replication vector.  
The primary sequence was input into the CCD - NKI site for secondary structure analysis (Figure 
20)
20
.  Results from these data were used in designing constructs for protein expression.  We 
chose to express three constructs: Full length, 15_578, and 62_578.  Crystal structures of the 
GAF A and GAF B have been solved independently of each other
53,57
.  Crystallization of both 
GAF domains together along with the HK and ATPase domains are important to understanding 
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how the transmission of signal is accomplished.  All constructs were terminated at residue 578 
on the C-terminus.  The N-terminal start of our constructs varied.  Along with secondary 
structure predictions, software was used to predict whether there were transmembrane regions of 
the protein.  From previous literature, there it was hypothesized that transmembrane helices were 
present allowing for the sensor region to have access to the signal 
50
.  Constructs including these 
regions have been expressed using an E.coli expression system, so they were included in our 
designed constructs
50
.  No signal peptide was discovered using SignalP 3.0 software, so the full 
length construct was included in the list
59
.  Since it is likely that there are signal sequences for 
Mycobacteria spp. that are not discovered, two other constructs were designed starting at 
methionine 15 (M15) and the third start is at glycine 61 (G61) proximal to the start of the GAF A 
domain.  Upon further analysis of the codon usage, we determined that codon optimization might 
help with increasing expression. Protein was submitted to GENSCRIPT™ for codon 
optimization. 
Each DevS construct was inserted into three expression vectors.  The vectors were 
pMCSG7, pET-32 EK/LIC (EMD Biosciences), and pCPD Lasso (Appendix C).  Each 
expression vector contained T7 promoters, IPTG inducible, and a his tag (hexa- or deca-).  
Vector pMCSG7 was described in previous chapters.  The pET32 EK/LIC vector fuses a 
thioredoxin protein N-terminal to the target protein connected to the via an enterokinase cleavage 
site to remove the tag.  The pCPD Lasso vector attaches the CPD fusion protein C-terminal to the 
target protein and is connected to the deca-his tag via a ten residue linker of serine and glycine 
residues.  Sequence verified sequences were transformed into BL21 (DE3) GOLD cells along 
with L-arabinose inducible GroEL/ ES.  Expression of DevS constructs were performed as 
described by Yukl et al. 
56
.  Cells were grown to an O.D.600 of 0.8 when then temperature was 
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lowered to 18
o
C.  An L-arabinose solution was added until a final concentration of 0.2% v/v.  
Cells were allowed to shake for 30 minutes.  IPTG was then added to the cells at a final 
concentration of 0.5 mM and left to grow overnight.   Cells were pelleted and resuspended in 50 
mL of lysis buffer (100 mM Potassium phosphate pH 7.4, 500 mM NaCl, 10% glycerol, 0.5 mM 
TCEP) per 2 Liters of culture.  Resuspended pellets were aliquoted into 50mL culture tubes then 
stored at -80
o
C. 
Cells were lysed in 50 mL of lysis buffer plus protease inhibitors, lysozyme, DNase, 5 
mM MgCl and 5 mM ATP.  MgCl and ATP were added to lysis mixture to help with any 
possible chaperone attachment to the target protein. Solution was allowed to equilibrate for 30 
minutes. Cells were lysed using a Branson Sonic dismembraner with 3 cycles on .5 sec pulse/ 1 
sec rest at 30% power.  Cell lysate turned a rose color due to the oxidation of the heme present in 
solution.  Lysed cells were centrifuged at 16 K RPM for 70 minutes at 10
o
C.  Samples were 
decanted collecting the supernatant.  Supernatant was passed through a 0.22 um syringe filter.  
Syringe filtered sample was loaded over a HisTrap HP column (GE Healthcare) collecting flow 
through.  Column was washed with lysis buffer until a protein signal could no longer be detected 
by Bradford assay or UV detection when using the AKTA Express® (GE Healthcare).  The 
column was then washed with 30 mM imidazole in lysis buffer, removing non-specifically bound 
material.  Protein was eluted from the nickel column using a 500 mM imidazole plus lysis buffer 
bump and fractions were collected.  The following step is where the purification procedure 
diverges for each expression system; LIC system, EK/LIC and CPD system.  Using the LIC 
system the protein was put into a dialysis membrane (7500 MWCO) with the addition of 0.5 mg 
of TEV protease.  Sample was dialyzed against 50 mM Tris pH 8.0, 100 mM NaCL, and 1mM 
DTT and left to go overnight at 4
o
C.  The EK/LIC was treated similarly to the TEV protocol, but 
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enterokinase was added instead.  Using the CPD system, a solution of inositol-6-phosphate 
(Ins6p) was added at a final concentration of 1 mM to elicit auto-cleavage.  Sample was allowed 
to gently shake overnight at 4
o
C.  Each reaction was again passed over a nickel column re-
equilibrated in lysis buffer, no imidazole, collecting flow-through.  The rose color was still 
present in the flow through.  A SDS - PAGE gel was run on lysate, flow through, elution, 
cleavage reaction, and second flow through fractions.  Gel was analyzed to see the presence of 
target protein and also to see if cleavage worked (Figure X.X).  Samples from the second nickel 
column were concentrated using a centrifugal concentrator MWCO of 30 kDa to a volume of 
less than 5 mL.  As the sample was concentrated the color of the sample increased in redness, 
indication that heme was bound to protein.  The concentrated sample was loaded over a 
Superdex S200 SEC that was pre-equilibrated in 10 mM Tris pH 8.0, 100 mM NaCl, and 0.5 
mM TCEP.  Peak fraction were collected and run on a SDS - PAGE gel to verify target protein.  
Fractions from the SEC 200 purification lacked the reddish color that was present throughout 
purification indicating a loss of bound heme.  Elution volume off the column also indicated that 
the protein was soluble aggregate. 
Discussion 
 Recombinant expression of DevS requires the addition of heme in the form of the ferric 
salt hemin (sigma-aldrich) along with charperones GroEL/ES
58
.  Omission of these cofactors 
contributes to a decrease in DevS production.  In our experiments we had no problems with the 
amount of expression, but misfolded expression 
 Signs of misfolded protein presented as a doublet around the molecular weight of DevS 
on a SDS – PAGE gel.  The lower band always co-eluted with DevS.  The molecular weight of 
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the band is similar to that of the calculated value for GroEL suggesting that DevS is misfolded 
and stuck within the chaperone.  One of the methods used to remove stuck chaperones is the 
addition of ATP to the lysis buffer.  It is hypothesized that the chaperones will turnover the ATP 
and cycle through until the target is clear of the complex.  During the lysis process, ATP was 
added to lysis buffer along with MgCl2 (added to protect the nickel column), but the secondary 
band still co-eluted.  Recombinant expression of full length DevS and DevS 62_578 has been 
achieved at low levels of expression, but never at high enough concentrations for crystallization. 
 One possible method to overcome misfolding is to decrease the temperature during 
growth to slow down the production and folding of the recombinant protein.  DevS expression, 
full length and DevS 62_578, were repeated using ArticExpress® cells in place of BL21 (DE3).  
GroEL/ES chaperones at low temperatures (<16
o
C) have a decreased activity
60
.  ArticExpress® 
cells have endogenous chaperones that are 100% active at temperatures between 4 and 12
o
C. 
 Recombinant DevS in the EK/ LIC TRX expression vector was transformed in 
ArticExpress® cells.  Method of expression was performed similarly as previously described by 
Yukl et al., except with changes to the cell type, the temperature was lower to 12
o
C and the 
induction was left to run for 36 hrs.  Cells were lysed at following prior protocols. Samples were 
run on a SDS – PAGE gel. Expression of DevS 62_578 seemed to work and we were able to 
separate the doublet band (Figure 20). 
 Purified DevS was concentrated using spin concentrator with a 30K MWCO to a volume 
of less than 5 mL.  Heme was still detected in solution due to the presence of the rose color.  
Sample is loaded over sizing column that has been equilibrated in 10 mM HEPES pH 8.0, 200 
mM NaCl, 1 mM TCEP, and 2% glycerol.  Peak fractions were collected based on 
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chromatogram (Figure 21) and fractions were run on a SDS – PAGE gel.  Collected fraction no 
longer was a rose color. During purification over the S200 sizing column the heme was removed 
from DevS.  The Heme co-factor was consistently lost after purification off the sizing column.  
After loss of heme, DevS would aggregate. 
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Figure Legends 
18. Figure 18 (a and b): GAF and PAS domain with heme bound. 
 
19. Figure 19: Secondary Structure Prediction Alignment of DevS 
 
20. Figure 20: Gel Purification of DevS 62_578 
 
21. Figure 21: Size Exclusion Chromatography of DevS 62_578 
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Figures        
 
Figure 1: Diagram of the primary sequence for HBHA aligned with a secondary structure 
prediction and the coiled-coil prediction. 
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Figure 2:  Far UV-CD spectra of regional HBHA constructs at 10 µM 
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Figure 3:  Thermal denaturation of HBHA constructs monitored at 222 nm. 
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Figure 4:  Absorbance detected analytical ultracentrifugation – sedimentation equilibrium 
traces with residual plots.  
A B C 
D E F 
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Figure 5:  Absorbance detected analytical ultracentrifugation – sedimentation equilibrium 
traces with residual plots. 
A B
B 
C 
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Figure 6:  Absorbance detected analytical ultracentrifugation – sedimentation equilibrium 
traces with residual plots. 
 
A B 
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Figure 7:  7.24 x10
4
 xg AUC Data of HBHA constructs plotted as a relation of molecular 
weight.   
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Figure 8: Schematic of HBHA Model. 
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Figure 9: Size exclusion chromatography traces of HBHA 6_111.
A 
B 
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Figure 10: SDS -PAGE gel of HBHA 6_111 + CPD.
A B C 
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Figure 11: Structure and Biosynthesis of ManLam 
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Figure 12: GDP-mannose Synthesis Pathway 
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Figure 13: Phosphohexomutase Coupled Assay Schematic 
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Figure 14: Size Exclusion Chromatography of Rv 3257c (Mtmanb).
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Figure 15: Ribbon Diagrams of Mt Man Model and PDB Structure 2FKF.
A B 
C 
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Figure 16: Charge potentials diagrams from Mtmanb model and 2FKF from the PDB 
A B 
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Figure 17: Charge potential diagrams from Mtmanb model and 2FKF rotated 90 degrees 
about the z-axis.                 
A B 
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Figure 1: (A)  GAF and (B) PAS domains with heme bound.
A B 
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Figure 19: Secondary Structure Prediction Alignment of DevS 
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Figure 20: Gel Purification of DevS 62_578 
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Figure 21: Size Exclusion Chromatography of DevS 62_578 
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Figure 22: Vector Diagram of Assembled Vector pCPD-Lasso 
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Table 1: HBHA Construct List 
Constructs Residues 
(Start and End) 
Amino Acid Number 
HBHA 1_199 1 to 199 202 
HBHA 6_199 6 to 199 197 
HBHA 6_156 6 to 156 154 
HBHA 6_111 6 to 111 109 
HBHA 6_99 6 to 99 97 
HBHA 6_88 6 to 88 86 
HBHA 6_138 6 to 138 136 
HBHA 20_199 20 to 199 183 
HBHA 6_199 L14A L15A 6 to 199 197 
HBHA 6_111 L14A L15A 6 to 111 109 
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Table 2: DICHROWEB Output (Secondary Structure Statistics for HBHA Constructs) 
Constructs Helix (%) Sheet (%) Turn (%) Unordered (%) Totals (%) 
HBHA 6_111 0.62 0.05 0.1 0.22 0.99 
HBHA 6_199 0.34 0.14 0.15 0.36 0.99 
HBHA 6_156 0.42 0.12 0.13 0.33 1 
HBHA 6_88 0.50 0.07 0.13 0.31 1.01 
HBHA 20199 0.21 0.2 0.16 0.41 0.98 
HBHA6_199 
L14A L15A 0.16 0.28 0.16 0.41 1.01 
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Table 3: HBHA Construct Melting Temperatures (Tm) 
Construct 
Number of amino acids Melting temperature (T
m
) 
(
o
C) 
Res. 1_199 202 58.5 ± 0.20 
Res. 6_199  197 60.0 ± 0.07 
Res. 6_156  154 58.2 ± 0.17 
Res. 6_138  136 58.0 ± 0.16 
Res. 6_111  109 52.5 ± 0.16 
Res. 6_99  97 40.0 ± 0.51 
Res. 6_88  86 40.0 ± 1.0 
Res. 6_199 L14A L15A  194 N.A. 
Res. 6_111 L14A L15A  109 N.A. 
Res. 20_199  183 N.A 
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Table 4: HBHA Construct Buoyant and Molecular Masses 
Construct  Calculated Mass 
(Da) 
Buoyant Mass 
(Da) 
Oligomer 
Res. 1_199 21675 43406 2.0 
Res. 6_199  21274 49117 2.3 
Res. 6_156  16973 34537 2.0 
Res. 6_111  12240 26377 2.2 
Res. 6_88  9867 19795 2.0 
Res. 6_199 L14A 
L15A  
21190 25350 1.2 
Res. 20_199  19926 23323 1.2 
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Appendix A: Reference Datasets Circular Dichroism and Synchrotron Radiation Circular 
Dichroism Spectroscopy of Proteins
69
.  
 
 
 Proteins included in each dataset are shown with X in the column of the data set. 
Name  Set 1  Set 2  Set 3  Set 4  Set 5  Set 6  Set 7  SP175 
Range 
(nm)  
178-
260  
178-
260  
185-
240  
190-
240  
178-
260  
185-
240  
190-
240  
175-
260 
                  
AAMY    X             
ABNG  X   X X   X X X† 
ACY5    X X           
ACY9    X X           
ADH    X X   X X     
ADK    X   X         
ALDO    X             
APP    X             
APRT    X             
AVDN    X             
AZU  X X X X   X X   
BAMY    X             
BB2C    X             
BGAL    X             
BLAC  X X X X   X X X† 
BNJN  X X X X X X X   
BPTI    X   X         
67 
 
CA1    X             
CANH    X X   X X X   
CAL    X             
CAT    X             
CER    X             
CGA    X X   X X X   
CHYT  X X X X X X X X 
CITS    X             
ColA    X X   X X     
CONA  X X X X   X X X 
CPAS    X   X X       
CPHY    X             
CYTC  X X X X X X X X† 
DHQ1    X             
DHQ2    X             
DNA1    X             
ECOR  X   X X   X X   
ELAS  X X X X X X X   
FERD    X             
FLVD  X X X X X X X   
GCR  X   X X   X X X 
GDC    X             
GEC    X             
GFP    X X   X X     
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GLOX    X             
GLUD    X             
GPB    X             
GPD  X   X X X X X   
GRS    X X   X X     
GSCR    X             
HAL    X             
HBN  X X X X X X X X 
HGDC    X             
HMRT  X X X X   X X   
HSA    X             
IFBP    X X   X X     
IGG    X             
INSL    X   X X       
JAC    X             
LACF    X             
LDH  X X X X X X X   
LEP    X             
LLEC    X             
LYSM  X X X X X X X X 
MBH    X             
MGLB  X X X X X X X X 
MON    X             
NMRA    X             
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NUCL    X   X         
OVAL    X             
OVOT    X             
OX20    X X           
PAPN  X X X X X X X X 
PARV    X   X         
PELC    X             
PGK  X   X X   X X X 
PGLU    X             
PGM    X             
PLA2    X             
PLEC    X             
PNMT    X             
PPSN  X X X X   X X X 
PRAL  X X X X X X X   
PROX    X             
PYK    X             
RHD    X X   X X X   
RNAS  X X X X   X X X 
RUBR    X   X         
SN06    X X           
SN70    X X           
STI    X             
STRP    X             
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SUBA    X             
SUBB  X   X X X X X   
SUBN  X   X X   X X   
SUDS  X X X X   X X X 
THAU    X             
T4LS  X X X X   X X   
THML  X X X X X X X   
TNF  X   X X   X X   
TPI  X X X X X X X X 
TRPN    X             
UBIQ    X             
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Appendix B:  Protein Crystallization Screens 
1. Qiagen® Screens: Classics, Classics Lite, pH Clear suite, JCSG+ Suite, JCSG 1 – 4, 
PACT suite, PEGs I and PEGs II suites, MPD suite, AmS04 suite 
2. Molecular Dimensions Screens: Morpheus™, PGA suite, and Clear Strategy I and II. 
3. Emerald BioStructures Screens: Wizards I and II  
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Appendix C:  High-Throughput E. coli expression system from MARTX protein, 
Cysteine Protease Domain 
 
 A barrier to protein crystallization is the production of high concentrations of properly 
folded recombinant protein.  Proteins non-native to a particular system (e.g E. coli) are likely not 
to express or to express as insoluble inclusion bodies.  In this work we assembled a vector that 
uses an auto-cleaving molecule to help speed up purification while also increasing protein 
expression.  Previous papers have shown how using the cysteine protease domain (CPD) of 
MARTX toxin as a way to purify recombinant proteins
61
.  Production of many constructs to test 
for crystallization requires a method of screening that can cope with the volume of constructs.  In 
building our construct, we looked at making the system more amenable to a high-throughput 
system.   
 The initial version of CPD vectors were generated for bench top columns, not for 
automated systems like the AKTA express.  Modifications were made to accommodate for the 
tighter resin packing and the higher flow rates found with piston pumps systems, along with 
expression in E. coli.  Codon usage is the single most important determinant in prokaryotic 
protein expression
62
.  We analyzed the CPD DNA sequence for rare codons with respect to the E. 
coli expression system.  The incidents of rare codons were not disproportionately high, but the 
incidences were clustered.  Rare codon clustering has be shown to cause translational stop and 
ribosome release
63
.  Use of competent cell types designed for rare codon expression, BL21 
(DE3) - RIPL and BL21 (DE3) - RIP, was also seen to work to some effect, but some more 
recent work has shown that codon bias presented in these cells causes more insoluble expression 
of the recombinant protein
64
.  We decided to have the CPD fragment codon optimized to express 
in E. coli.  A codon optimized cDNA of CPD was ordered from GenScript™.  While creating the 
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CPD cDNA, we also had GenScript™ remove all possible restriction sites.  This facilitated 
insertion of cloned DNA into different expressions vectors.  Along with codon optimization we 
expanded the hexa-his tag to a deca-his tag along with a linker.  Much work has been done to 
determine the most effective organization for a histidine tag
65
.  Labs have tried different sizes, 
oligo numbers, and with and without linkers
66
.  A combination of a linker length around 11 with 
a deca-his tag was seen to be best for immobilization of the tag to a surface
67
.  The deca-his tag 
has a greater affinity for the Nickel column allowing for higher concentrations of imidazole 
during load and wash steps to remove non-specifically bound material.  Lastly a linker region of 
10 amino acids, consisting of glycine - serine repeats, was added between the CPD and the deca-
his tag to decrease the likelihood of the tag being incorporated into the fold of CPD and 
increasing access to the Ins6p site due to increased degrees of freedom with a flexible linker. 
Design 
 Our CPD vector was build on the pET22b vector backbone (figure 22).  The pET vectors 
use a T7 promoter-driven system, where control of corresponding RNA polymerase is IPTG 
inducible.  This system allows for a level of control based upon the concentration of IPTG added.  
The pET22b backbone has built-in Ampicillin resistance to help with the selection process 
during transformation into E. coli for replication or protein expression.  Another benefit of the 
pET22b vector is the presence of the pelB leader sequence.  When the pelB leader sequence is 
coded N-terminal to the target protein the E.coli transports synthesis of the protein from the 
cytoplasm to the periplasm.  Proteins that form inclusion bodies or aggregates in the cytoplasm 
due to the presence of disulfide bonds, fold better in the periplasm
68
.  In using the pET22b there 
is greater flexibility in protein expression.  The codon optimized CPD gene was amplified from 
pUC19 using PCR where the 3’ primer included a sequence that would encode for a linker region 
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of serines and glycines (gly - gly - ser x3) along with 4 extra histidine residues for the C-terminal 
tag. CPD was inserted into the pET22b vector using XhoI and BamHI restriction endonucleases.  
A target protein can be inserted into the new vector pET22b + LASSO using two different 5’ 
restriction sites.  To remove the pelB sequence the protein is inserted using the NdeI site, while 
the NcoI site is used to keep the target protein within the reading frame of the pelB sequence.  
The BamHI site is used for the 3’ end of the insert.  When designing primers to insert the target 
gene it is important to look at the primary sequence of the protein. If there is a leucine near the 
end of a construct then the codon for leucine does not have to be included in the primer, but if no 
leucine is present then the leucine codon needs to be added 3’ to the target protein sequence for 
the 3’ primer.  This leucine is important for CPD cleavage. 
Results 
 Use of the CPD vector has been exclusive to the Relaxase class of proteins studied in the 
Redinbo.  The CPD system has been shown express VirD2 (A. tumefaciens) and the relaxase 
from a vancomysin resistance plasmid (S. aureus).  The proteins were previously expressed as 
inclusion bodies using the T7 promoter system in the Redinbo laboratory.  Using the CPD 
system, the proteins remain soluble (data not shown).  In all instances protein purification time is 
decreased from 2 - 3 days to a minimum of 7 hours in the case of VirD2.     
Figure Legend: 
Vector Diagram of Assembled Vector pCPD-Lasso: Vector diagram was generated using 
Vector NTI ™ (Invitrogen ™).  Restriction sites used to insert target protein sequence are listed I 
red on the vector.  Important features of the vector are listed in bold black.  The direction of the 
arrows notes the direction in which the features are transcribes or replicated. 
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